Tufts model estimates 82x ROI and up to $21 million in value from Medable AI agent

Positive

AI Analysis

Summary

Tufts CSDD and Medable announced an analysis estimating Medable's Clinical Monitoring Agent could deliver 82x ROI for phase 3 trials and 64x for phase 2, with approximately $21 million in net present value.

Clinical Trial Data

Phase

2,3

Importance:4/10

Sentiment:

0.70

AIclinical trial monitoringphase 2phase 3ROI analysiscost reduction

Related Companies

$TRAX

Read the original article

Published by Drug Discovery & Development on August 26, 2026 10:24 PM

Read Original